I. Lung Nodule Classifier Refinement

Overview
The objective of the classifier refinement study was to optimize a proteomic lung nodule classifier for diagnostic use with an enhanced mass spectrometry workflow. Our prior work reported a classifier comprised of 13 diagnostic and 6 normalization proteins (discovery classifier) based on proteomic analyses of archival plasma samples using the AB SCIEX QTRAP® 5500 LC/MS/MS System (Framingham, MA) (i.e., development platform) 1 . The subsequent refinement of the classifier for clinical use was performed in a clinical laboratory adhering to CLIA specifications using standard operating procedures (SOPs), which incorporated 1) stable isotope-labeled standard (SIS) peptides and 2) the Agilent 6490 LC/MS system (Agilent Technologies, Santa Clara, CA) (i.e., deployment platform). The operational and technological enhancements yielded the diagnostic classifier comprising five diagnostic proteins (which were a subset of the original 13 diagnostic proteins in the discovery classifier) and the same six normalization proteins. The diagnostic classifier composition and the coefficients for each constituent protein were fully defined, i.e., "locked down," prior to the initiation of the validation study.
Methods
Study Design
Proteomic analyses were performed using archival plasma samples from the Discovery sample set analyzed in the development of the discovery classifier 1 
Deployment Platform Plasma Sample Analysis
A total of 100 plasma samples (cancer, n=50 and benign, n=50) in the intended use population were selected based on sample availability from the 143 plasma samples used in the discovery classifier study 1 . The samples were analyzed in 5 experimental batches, with each batch containing 10 cancer samples, 10 benign samples and 4 aliquots of a pooled human plasma standard (HPS) sample (Bioreclamation, Hicksville, NY).
Analysis of plasma samples was performed as previously described 1 with the following modifications for the deployment platform. Immunoaffinity chromatography was performed with columns comprised of a 2:1 ratio of IgY14 and SuperMix resins (Sigma Aldrich, St. Louis, MO) with a total bed volume of 10 ml. Separations were performed on a 1260 Bio-inert HPLC system (Agilent Technologies) with the buffer and gradient conditions as previously described. were measured by the abundance ratios of the corresponding endogenous and SIS peptides and normalized by the abundance ratios of the six normalization proteins (ms submitted for publication).
Logistic Regression Models
For each evaluated classifier, a classifier score was calculated for each sample using a logistic regression model as follows
where
Here α was a classifier-specific constant, {β ! } were protein-specific coefficients, {γ !" } were coefficients modeling interactions between two proteins, N was the total number of proteins in the classifier, and {P ! } were Box-Cox transformed 2 protein abundances,
where P ! was the normalized protein abundance and λ ! was the power for the transformation.
For models without interaction terms, all {γ !" } were fixed to zero. Box-Cox transformations were performed so that transformed protein abundances followed normal distribution approximately. The value of λ ! was determined by searching its optimal value from -2 to 2 using the maximum-likelihood method 3 .
Classifier Refinement
Protein quantification data from the deployment platform were used for refinement of the 
Statistical Analyses
All data analyses were performed with STATA, MATLAB, and/or R. Table S2 .
Results
Refinement
MRM-MS data were successfully obtained for 94 samples, as shown in Table S1 and File S1, and 15 HPS samples. Three clinical samples yielded partially integrated peaks for several of the discovery classifier proteins; these samples were analyzed in the dataset, but not utilized for the training of the diagnostic classifier.
Table S1. Plasma Sample Clinical Characteristics
Shown are the clinical characteristics for the 94 samples for which MRM data were successfully obtained and the associated subject demographic and lung nodule radiographic data. (*Pack-year data were not available for two cancer and three benign samples. ¶ Data provided for former or current smokers only. Data analyses performed using either the ‡ Fisher's exact or † Mann-Whitney tests.)
Eight of the 13 discovery classifier diagnostic proteins did not satisfy the criteria for inclusion in the diagnostic classifier, as shown in Table S2 . FIBA was targeted by the depletion column and also subject to technical variability 5 , while GSLG1 yielded weak signals on the deployment platform. The assay specificity for the LRP1 peptide could not be confirmed as the SIS peptide yielded an elution time differing from that of the endogenous peptide. 
Table S2. Diagnostic and Normalization Proteins in the Discovery and Diagnostic Classifiers
Refinement of the previously reported discovery classifier using 94 samples in the discovery sample set for the discovery classifier 1 was performed using SIS peptides and a different MRM-MS technology platform. Shown are the transitions and coefficients, β1 and β2, for the discovery classifier and diagnostic classifier proteins. The analyses of the proteins on the development and deployment platforms yielded the diagnostic classifier after the exclusion of eight discovery diagnostic proteins based on technical and statistical criteria. The use of MCCV simulations to assess mutual interactions among the five remaining proteins, ALDOA, COIA1, FRIL, LG3BP and TSP1, identified an interaction between COIA1
and FRIL that improved performance significantly, resulting in the inclusion of the COIA1-FRIL interaction term in the diagnostic classifier. The performance of the diagnostic classifier included a sensitivity of 93.6% (95% CI: 82.5-98.7%) and a specificity of 36.2% (95% CI: 22.7-51.5%), with an overall AUC of 0.690 (95% CI: 0.587 -0.782), as shown in Fig. S1 . These data were comparable to those previously reported for the discovery classifier 1 and consistent with requirements for identifying the absence of disease, e.g. benign lung nodules.
Figure S1. Diagnostic Classifier Performance
Shown is the area under the receiver operating characteristics (ROC) curve (AUC) of the diagnostic classifier based on the proteomic analyses of 94 plasma samples on the deployment platform. Note that the overall AUC was 0.690 (95% CI: 0.587 -0.782) and similar to that previously reported for the discovery classifier The use of computed tomography (CT) technology has grown annually by 6.5% in the U.S. and yielded 85 million studies in 2012 6 , including a 15.9% proportion of chest CT scans 7 ;
with 18 to 51% of chest CTs scans estimated to demonstrate a lung nodule 8, 9 , the yearly number of pulmonary nodules identified may approach millions, most of which are benign 8 . Notably, stage IA lesions of lung nodule size, i.e., 3 cm or less, represent 26% 10 of the 228,000 yearly estimated cases of lung cancer in the U.S in 2013 11 , thus constituting a small minority of all lung nodules identified.
Methods
Definition of Validation
To achieve the rigor necessary for the introduction of a multivariate biomarker classifier into clinical use, the design and execution of the study were implemented in accordance with the guidelines stipulated by the Institute of Medicine (IOM) for the clinical validation of an omicsbased test 12 (Table S4 ) and the REporting recommendations for tumor MARKer prognostic studies (REMARK criteria) (Table S5 ) 13 . The study was designed to validate the clinical performance of an 11-protein classifier that discriminates between lung nodules associated with either non-small cell lung cancer (NSCLC) or benign processes (as detailed in Lung Nodule
Classifier Refinement). In addition, a key technical element of the validation was the evaluation of the classifier in a clinical laboratory operating under the auspices of the Clinical Laboratory Improvement Amendments (CLIA) of 1988 12 , which ensure the quality of laboratory testing in the U.S. Importantly, the analytical validation, defined for omics tests as the assessment of a test's ability to accurately and reliably measure the analytes of interest in the clinical laboratory and in specimens representative of the population of interest 12 , was previously completed in the sponsor's CLIA laboratory (ms in preparation). Additional IOM criteria included the following (Table S4) : analysis of clinical samples representative of the "intended use population," defined as the target patient subgroups satisfying specific clinical criteria for whom the test will be applicable; analysis of samples from multiple centers; the majority of samples used in the validation study must originate from non-discovery sites; a "locked down" classifier; a data analysis plan based on a pre-specified strategy for use of a classifier value, to discriminate the absence or presence of disease, under the oversight of an independent biostatistician; and a blinding strategy in which the clinical information about the patients, plasma specimens and lung nodule outcomes were not available to individuals participating in the study execution, or the investigators and sponsor data analysis team, until after completion of the independent data analysis 12 . The defined test method should include the fully specified computational procedures that were locked down at the end of the discovery phase, which will be used for analysis of the assay results to yield the final test result that is used as the interpretive criteria for the omics-based test. 
Yes
Independent Samples
The optimized test should be evaluated for clinical/biological validity using an independent specimen set, consistent with the intended use for the test.
Blinding
The expected or previously determined test results for the validation set of specimens and clinical information about the patients from which the specimens were derived should not be available to the individuals performing and interpreting the test results to reduce the chance that results will be affected by conscious or unconscious bias. This process of blocking this information from the tester is called blinding of the specimens. Intended Use Clinical/biological validation is performed using specimens comparable to the patient specimens on which the test will eventually be used, and a sufficient number of specimens to allow statistical assessment of the test performance in relation to the specimen characteristics. 
Study Inclusion and Exclusion Criteria
The subject inclusion criteria for study eligibility included the following: prior enrollment in study approved by the participating institution's ERB or IRB; provision of informed consent for prior study; minimum age of 40 years; any smoking history status (never, former, or current);
any co-morbid conditions; any prior malignancy; prior provision of a blood specimen collected in a K2-EDTA-containing blood collection tube; and blood specimen processed and archived as stipulated by the prior study's protocol at each participating site. The lung nodule radiologic and pathologic inclusion criteria for study eligibility included the following: radiographic size of nodule at least 8 mm and up to 30 mm in size; any lobar location; any radiologic; i.e., chest CT, appearance; a histopathologic diagnosis of non-small cell lung cancer (NSCLC); a histopathologic diagnosis of a benign process; and a clinical diagnosis of a benign etiology based on no change in nodule size or appearance for two years after the baseline CT scan 14 . The study exclusion criteria for subjects included the lack of nodule size or availability of histopathologic diagnosis and a histopathologic diagnosis of small cell lung cancer.
Proteomics Analysis
The handling and processing of all plasma samples from participating institutions were performed as required by CLIA and stipulated in the sponsor's standard operating procedures (SOPs) for the following: clinical sample receipt; depletion HPLC system suitability; depletion of test batch; lyophilization of test batch; enzymatic digestion of test batch; spiking of stable isotope-labeled internal standard (SIS) peptides into test batch; solid phase extraction; LC-MS system suitability; LC-MS analysis of test batch; data analysis and quality control (QC) of LC-MS results; and generation of the classifier score using the laboratory information management system (LIMS). To avoid potential biases due to sample handling during column depletion of high abundance plasma proteins and the proteomic analysis of samples in batches, an external biostatistician assigned samples to specific columns and batches based on a pre-defined requirement to ensure samples were distributed demographically across columns and batches.
Experimental and computational details were identical to those described in the previous section (Lung Nodule Classifier Refinement) with the exception that a volume of 50 µl instead of 60 µl of plasma per sample was diluted and injected in the depletion process.
Protein Expression Classifier
The protein expression classifier is an algorithm derived by logistic regression analysis that yields a score between 0 to 1 based on the measured value of the expression of each of its 5 constituent diagnostic proteins, and their associated derived coefficients, and 6 normalization proteins (Table 1 Table 1 . The involvement of the diagnostic proteins in molecular pathways
implicated in the systemic pathogenesis of lung cancer substantiates the classifier 's biologic rationale, as previously described 1 .
Data Analysis
The which are common predictors used in lung nodule assessments for malignancy 18, 19 .
Validation Study Cohort and Blinding Strategy
To avoid the potential introduction of bias, the study was conducted in a blinded manner in which individuals participating in the study execution, e.g., laboratory handling and proteomic analysis of samples, and the data analysis were blinded to the clinical information about the patients, plasma specimens and lung nodule outcomes, i.e., cancer or benign. An independent team of biostatisticians performed the assignment of samples using a batching protocol design, and executed the data analysis plan to achieve both study objectives. Separate data files containing either clinical data from the participating sites or classifier scores derived from the laboratory and bioinformatic protocols for each of the study cohort samples were provided to the biostatistical team. The biostatisticians executed the data analysis plan by using a master key to link the subject and sample identification numbers with the laboratory sample identification numbers from the laboratory information management system (LIMS). 
Validation of the Protein Expression Classifier
The statistical plan to achieve the validation of the classifier prioritized sensitivity rather than specificity to enable its use for the identification of lung nodules due to benign etiologies.
In prior work, the classifier was developed based on the bioinformatic optimization of its protein constituents for sensitivity and negative predictive value 1 . The validation plan was predefined and required the achievement of two sequential objectives evaluating: 1) the classifier's diagnostic performance based on the pAUC of its ROC curve 15,21 associated with higher sensitivity, and 2) the sequential evaluation of individual classifier scores to determine the maximum value for its diagnostic range. The fixed sequence procedure 16, 17 was used to control the overall error rate in testing the two objectives.
The first objective was to demonstrate that the pAUC of the classifier's ROC curve bounded by a sensitivity greater than 0.8 was significantly larger than the corresponding pAUC due to chance (pAUC 0 ). The null hypothesis, H1, was expressed as pAUC<pAUC 0 . The use of the pAUC method 15, 21 was based on the rationale that only a portion of the ROC curve, i.e., the region of higher sensitivity, may be clinically relevant to the classifier's intended use (Fig. S2 ) 22 .
For the lung nodule protein expression classifier, the relevant pAUC focuses on the ROC curve's region of higher sensitivity to achieve the goal of identifying benign lung nodules, i.e., the absence of NSCLC. A sensitivity of 0.8 was chosen so that a range of values corresponding to an NPV >90% for estimated prevalence of NSCLC between 20 to 25% in the intended use population could be tested (Fig. S3) . The null hypothesis, H1, was rejected if the one-sided lower 95% confidence bound (pAUC L ) of pAUC was no less than pAUC 0 , which may be expressed as pAUC L ≥ pAUC 0 = 0.02. The calculation of the pAUC to test the null hypothesis, H1, was performed in 10,000 bootstrap samples using the function "comproc" in R package "pcvsuite" 15, 21 .
The second objective was to define the applicable diagnostic range for identifying benign lung nodules using the fixed sequence procedure method. Assessment of the second objective was to be performed only if the first objective were achieved. The statistical requirement was to demonstrate that there is a classifier score serving as a reference value, T, such that the fraction of benign samples among those samples with a classifier score less than or equal to T is significantly higher than the fraction of benign samples in the study cohort 1-SEN) ], using R function "rocreg" [23] [24] [25] , where SPC is the specificity, SEN is the sensitivivty, and Φ(x) is the normal cumulative distribution function. Second, the sensitivity at the reference value T was determined by matching the total benign classifications from the actual data with the total benign classifications from the fitted data. The corresponding specificity was given by the binomial form. Third, the one-sided lower 95% lower confidence bound frac T,L was calculated using Jeffreys interval as implemented in R function "binom.bayes" in package "binom." The sequence of classifier scores as candidate reference values for T ranged from 0.38 to 1.00, with the sequence beginning at 0.38 and increasing by 0.01.
Specifically, testing began with H2 0.38 , whose rejection in turn would enable testing of H2 0.39 and so forth, until the acceptance of any H2 T hypothesis, which terminated the testing procedure at the specific reference value, T, without further testing of H2 T at larger values of T.
In summary, the validation of the protein expression classifier required the rejection of the null hypothesis, H1 where pAUC<pAUC 0 , and the sequential rejection of the null hypothesis, H2 defined as frac T < frac 0 , over a range of scores of T, yielding a clinically validated classifier with the same range of scores of T for use in identifying a lung nodule as benign.
Figure S2. Rationale For Use Of The Partial Area Under The Curve For Diagnostic Test Development
Shown are the receiver operating characteristic (ROC) curves for two hypothetical tests, A and B, which have identical areas under the curve (AUC), i.e. AUC testA =AUC testB 22 . However, the morphology of the ROC curves for the two tests differ. Note that the ROC curve for test A favors higher specificity, suggesting a potential role to help clinicians "rule in" disease. By contrast, the ROC curve for test B favors higher sensitivity, suggesting a potential role to help them "rule out" disease. The partial area under the ROC curve (pAUC) for an ROC curve occurring by chance (dotted line) with a lower bound of a sensitivity of 0.8 (grey line) is 0.02, as determined by the formula for the area of a triangle, i.e., 0.5 x 0.2 x 0.2; therefore, the pAUC 0 , denoted by the area, a, equals 0.02. The pAUC for the classifier's ROC curve (solid black line) is denoted by the area, a+b. Note that the values for 1-specificity for the portion of the classifier's ROC curve defining pAUC correlate with the lower range of values for specificity for each corresponding value of sensitivity. Therefore, the classifier's performance is based on the pAUC with a range of higher sensitivity, but is necessarily associated with a lower range of specificity.
Protein Expression Classifier Performance and NPVs
To facilitate clinical use of the protein expression classifier for lung nodule decisionmaking, a range of positive and negative predictive values was determined based on the sensitivity and specificity for the classifier scores, and also an estimate of the prevalence of NSCLC in the target intended use population. The estimate was necessary since the prevalence of NSCLC for patients greater than age 40 with any tobacco history and a lung nodule between 8 to 30 mm in size is unknown. A lower bound of the prevalence of NSCLC may be illustrated by the 14% overall lung cancer prevalence in the diverse population of an integrated health care system, inclusive of all ages and any tobacco history 26 ; the upper bound may be illustrated by the 29.7% NSCLC prevalence for lung nodules 21 to 30 mm in size in the National Lung
Screening Trial (NLST) study population, ranging in age from 55 to 74 and having greater than or equal to a 30 pack-year smoking history 27 . To estimate the NSCLC prevalence for the intended use population, a calculation was performed based on the weighted average of the NSCLC prevalence in patients with 8 to 20 mm lung nodules and that in patients with 21 to 30 mm lung nodules, using the relative proportions of both nodule subgroups (Eq. 7).
Equation 7
The values for prevalence [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , proportion [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and proportion [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] were derived from a national multi-center chart review study of patients with lung nodules 8 to 20 mm in size between 2008 to 2013, which abstracted subject demographic and medical history data, lung nodule radiologic and pathologic data, and diagnostic test resource utilization data from the medical chart for each enrolled subject (unpublished data). To enroll subjects with 8 to 20 mm lung nodules satisfying
the enrollment criteria, the subject identification process retrospectively evaluated 2,451 medical charts of patients with lung nodules, and yielded a distribution of nodule size for the less than 8 mm, 8 to 20 mm and 21 to 30 mm subgroups of 39.4%, 39.9% and 9.9% and an additional 10.7% whose lesion size exceeded 30 mm (i.e., masses); however, no clinical data, e.g., lung
nodule cancer or benign status, was obtained for the non-enrolled subjects. Therefore, the values for proportion [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and proportion [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] used for the prevalence estimate were 0.399 and 0.099, respectively. The 21.5% value for prevalence [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] was derived from the observed prevalence of NSCLC in the chart review study 8 to 20 subgroup. The value for prevalence [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] is based on the National Lung Screening Trial baseline (T0) screening data and the outcome for lung nodules 21
to 30 mm in size, with 29.7% of 195 subjects having a diagnosis of lung cancer 27 , which is the largest reported dataset for this nodule size subgroup. Based on equation 7, the estimated prevalence of NSCLC for the intended use population with 8 to 30 mm lung nodules is 23.1%.
In summary, the NSCLC prevalence of 23.1% used to calculate the NPV for the validation study cohort incorporated NSCLC prevalence data and lung nodule subgroup data from a multi-center chart review study of 8 to 20 mm lung nodules and NLST data.
Independence between Classifier Score and Clinical Parameters
To compare the distributions of the classifier scores for categorical variables, the MannWhitney test was used for two categories and the Kruskal-Wallis test was used for more than two assessed by fitting into a linear regression model. STATA version 12.1 was used to perform the correlation analyses.
Characterization of the Classifier's Incremental Diagnostic Value
To determine the incremental diagnostic value of the protein expression classifier, the performance of the classifier was evaluated in conjunction with common risk factors for the prediction of malignancy 18, 19 . Using logistic regression, a clinical model was fitted with age, at 80% sensitivity were estimated with bias corrected 95% confidence intervals. The integrated
discrimination improvement indexes (IDI) were estimated with 95% confidence interval and its significant tested 28 . The analyses were performed using STATA software, version 13.1.
Results
Validation Study Intended Use Population
Characterization of the subject demographic and tobacco use history, and lung nodule radiologic and pathologic data established a clinical phenotype for the study cohort that is representative of the protein expression classifier's target intended use population ( Table 2 , File S2). The median age of subjects (n=141) with malignant (n=78) and benign (n=63) lung nodules was 65 years, with interquartile ranges (IQR) of 59-72 years and 56-73 years, respectively. The cancer and benign subgroups were comprised of 45% and 57% male subjects, respectively. The never smoker subgroup comprised 14% of both the cancer and benign subgroups; subjects who were former smokers comprised 62% or 65% of the cancer or benign subgroups, while those who were current smokers comprised 24% or 21% of the cancer or benign subgroups, respectively. In addition, the median tobacco use history in pack-years (PKY) was 40 PKY for subjects with malignant lung nodules and 30 PKY for those whose lung nodules were of benign etiology, with IQRs of 30-60 PKY and 21-63 PKY, respectively. No differences in the subject demographic parameters were statistically significant.
The validation study cohort included 141 lung nodules from 141 subjects, which were independent of any prior proteomic analyses used for discovery or verification of the lung nodule protein expression classifier ( 
Validation
Two metrics were used for the validation of the protein expression classifier for lung nodules: the first was the partial area under the receiver operating characteristic (ROC) curve (pAUC) 15 for the classifier; and the second was the sequential evaluation of candidate reference values to identify lung nodules with classifier scores at or below the reference values as benign.
The fixed sequence procedure 16, 17 was used to control the overall error rate in the study and required the successive rejection of two separate hypotheses, H1 and H2, to validate the classifier at a specific maximal reference value.
The use of the method of partial AUC 22 highlighted the portion of the AUC curve with higher sensitivity, which is important for diagnostic tests that prioritize NPV to define the absence of disease 29 . Similarly, the objective of the protein expression classifier is to identify lung nodules as benign, i.e. the absence of NSCLC. The classifier achieved the first study objective as the mean pAUC value for the portion of the classifier's AUC curve bounded by a sensitivity of 0.8 was 0.045; the pAUC L (the one-sided lower 95% confidence bound) for the classifier was 0.026, which was greater than the value of 0.02 for pAUC 0 (the same area for a hypothetical test whose AUC curve might have been achieved by chance alone), thereby enabling rejection of the null hypothesis H1: pAUC L < pAUC 0 . The overall AUC for the validated classifier was 0.615, which is similar to the 0.62 AUC previously shown for the classifier proteins 1 .
The completion of the first objective, i.e., the rejection of H1, enabled testing of the second objective using the fixed sequence procedure. The second objective was to demonstrate that a specific classifier score could be used as a reference value to identify those lung nodules with scores at or below the reference value as benign. The classifier was validated with reference values between 0.38 and 0.47. Implementation of the fixed sequence procedure involved the sequential testing of increasing classifier scores as a candidate reference value to evaluate the classifier's performance. The second objective was achieved and defined an upper limit reference value of 0.47 that enabled rejection of the null hypothesis, H2.
From the outset, the goal was to develop a classifier prioritizing high sensitivity to achieve a target NPV of 90%. That is, the strategic optimization of NPV guided the following:
biospecimen selection during classifier discovery and verification; the bioinformatic modeling to identify the best performing proteins in a group to derive a classifier that discriminated benign from malignant lung nodules; and the final refinement of the classifier to 5 diagnostic proteins optimized on the MRM-MS proteomics platform in the CLIA laboratory. The bioinformatic derivation of the classifier's diagnostic proteins 1 enabled optimization of the classifier's sensitivity and its pAUC for use in identifying benign lung nodules.
In summary, the validation of the protein expression classifier achieved two objectives which optimized its partial AUC based on the higher range of sensitivity and also derived the upper limit of the classifier score range for use as reference values to identify benign lung nodules. *Since no sample had a classifier score in this range, the value of 0.980 was set as the ceiling of the last value (0.972) with actual data.
Figure S4. Protein Expression Classifier Performance
A reference value (RV) is a specific score at or below which the classifier may assign a likely benign result to a given plasma specimen, based on the measured values of the classifier's constituent proteins. Classifier scores between 0.18 and 0.47 may be used as a reference value.
Shown is the performance of the classifier for all samples (n=141, including cancer n=78 and benign n=63) for the validation study cohort (prevalence of 0.55) or for the target population (n=1,000, weight adjusted cancer prevalence of 23%), using reference values of either 0.36 or 0.47. The value of 0.47 is shown based on the pre-specified criterion for validation of the classifier using the fixed sequence procedure, and the value of 0.36 is shown to illustrate a diagnostic performance of 90% NPV. 
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